Author's reply to page: "Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept"

CNS Drugs

Volumn 27, Issue 5, 2013, Pages 399-402

  Tobinick, Edward ^a,b,c  

^a Institute of Neurological Recovery   (United States)

^b Institute of Neurological Recovery   (United States)

^c Institute of Neurological Recovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR;

ACQUIRED BRAIN INJURY; BRAIN DEGENERATION; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG APPROVAL; EXPERIMENTAL THERAPY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE PATIENT; TRAUMATIC BRAIN INJURY; WHITE MATTER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN INJURIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; STROKE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878578871     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0058-x     Document Type: Letter

References (54)

1. Wolinsky H. Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against 'accepted wisdom'. EMBO Rep. 2008;9(5):416-8.
2. Sobel RK. Barry Marshall. A gutsy gulp changes medical science. US News World Rep. 2001;131(7):59.
3. Bauer HH. Knowledge monopolies as a new phenomenon in science. Dogmatism in science and medicine: how dominant theories monopolize research and stifle the search for truth. Jefferson: McFarland; 2012. p. vii.
4. Page SJ. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2013. doi: 10.1007/s40263-013-0057-y.
5. Smith C, Gentleman SM, Leclercq PD, et al. The neuroinflammatory response in humans after traumatic brain injury. Neuropathol Appl Neurobiol. 2012. doi: 10.1111/nan.12008.
6. Johnson VE, Stewart JE, Begbie FD, et al. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013;136(Pt 1):28-42.
7. Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother. 2001;55(5):258-63.
8. Hughes JL, Beech JS, Jones PS, et al. Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat. Neuroimage. 2010;49(1):19-31.
9. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci. 2008;28(9):2221-30.
10. Price CJ, Wang D, Menon DK, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke. 2006;37(7):1749-53.
11. Chio CC, Lin JW, Chang MW, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem. 2010;115(4):921-9.
12. King MD, Alleyne CH, Dhandapani KM. TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett. 2013. doi: 10.1016/j.neulet.2013.02.051.
13. Chio CC, Chang CH, Cheong CU, et al. Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha. BMC Neurosci. 2013;2013(14):33.
14. Hughes JL, Jones PS, Beech JS, et al. A microPET study of the regional distribution of [11C]-PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation. Neuroimage. 2012;59(3):2007-16.
15. Folkersma H, Boellaard R, Yaqub M, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med. 2011;52(8):1235-9.
16. Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011;25(2):145-55.
17. Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012;26(12):1051-70.
18. Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today. 2009;14(3-4):168-77.
19. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs. 2009;23(9):713-25.
20. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother. 2010;10(6):985-1002.
21. Barone FC, Parsons AA. Therapeutic potential of anti-inflammatory drugs in focal stroke. Expert Opin Investig Drugs. 2000;9(10):2281-306.
22. Chou SH, Feske SK, Atherton J, et al. Early elevation of serum tumor necrosis factor-alpha is associated with poor outcome in subarachnoid hemorrhage. J Investig Med. 2012;60:1054-8.
23. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128(3):519-48.
24. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem. 2009;16(24):3152-67.
25. Esposito E, Cuzzocrea S. Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci. 2011;32(2):107-15.
26. Kato K, Kikuchi S, Shubayev VI, et al. Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience. 2009;160(2):492-500.
27. Marchand F, Tsantoulas C, Singh D, et al. Effects of etanercept and minocycline in a rat model of spinal cord injury. Eur J Pain. 2009;13(7):673-81.
28. Miller AH, Haroon E, Raison CL, et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013. doi: 10.1002/da.22084.
29. Nathoo N, Caris EC, Wiener JA, et al. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007-14 (discussion 14).
30. Rossi D, Martorana F, Brambilla L. Implications of gliotransmission for the pharmacotherapy of CNS disorders. CNS Drugs. 2011;25(8):641-58.
31. Shen CH, Tsai RY, Shih MS, et al. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg. 2011;112(2):454-9.
32. Shen CH, Tsai RY, Tai YH, et al. Intrathecal etanercept partially restores morphine's antinociception in morphine-tolerant rats via attenuation of the glutamatergic transmission. Anesth Analg. 2011;113(1):184-90.
33. Tobinick E. Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):99-109.
34. Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.
35. Tsuda M, Masuda T, Tozaki-Saitoh H, et al. Microglial regulation of neuropathic pain. J Pharmacol Sci. 2013;121(2):89-94.
36. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134(4):330-4.
37. Horrobin DF. Effective clinical innovation: an ethical imperative. Lancet. 2002;359(9320):1857-8.
38. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx. 2004;1(3):341-7.
39. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-92.
40. Cumming TB, Bernhardt J, Linden T. The Montreal Cognitive Assessment: short cognitive evaluation in a large stroke trial. Stroke. 2011;42(9):2642-4.
41. Dong Y, Sharma VK, Chan BP, et al. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci. 2010;299(1-2):15-8.
42. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-9.
43. Pendlebury ST, Cuthbertson FC, Welch SJ, et al. Underestimation of cognitive impairment by Mini-Mental State Examination versus the Montreal Cognitive Assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010;41(6):1290-3.
44. Schweizer TA, Al-Khindi T, Macdonald RL. Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2012;316(1-2):137-40.
45. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry. 2007;52(5):329-32.
46. Toglia J, Fitzgerald KA, O'Dell MW, et al. The Mini-Mental State Examination and Montreal Cognitive Assessment in persons with mild subacute stroke: relationship to functional outcome. Arch Phys Med Rehabil. 2011;92(5):792-8.
47. Wong GK, Lam S, Ngai K, et al. Evaluation of cognitive impairment by the Montreal Cognitive Assessment in patients with aneurysmal subarachnoid haemorrhage: prevalence, risk factors and correlations with 3 month outcomes. J Neurol Neurosurg Psychiatry. 2012;83:1112-7.
48. Demonaco HJ, Ali A, Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy. 2006;26(3):323-32.
49. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009;22(2):119-25.
50. Beck JM, Azari ED. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J. 1998;53(1):71-104.
51. American Psychiatric Association. The principles of medical ethics: with annotations especially applicable to psychiatry. 2001st ed. Washington, D.C.: American Psychiatric Association; 2001.
52. Ghaemi SN, Goodwin FK. The ethics of clinical innovation in psychopharmacology: challenging traditional bioethics. Philos Ethics Humanit Med. 2007;2:26.
53. American Academy of Pediatrics. Committee on drugs: uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002;110(1):181-3.
54. Hachinski V, Donnan GA, Gorelick PB, et al. Stroke: working toward a prioritized world agenda. Stroke. 2010;41(6):1084-99.